Chongqing Genrix Biopharmaceutical Future Growth
Future criteria checks 2/6
Chongqing Genrix Biopharmaceutical is forecast to grow earnings and revenue by 47.6% and 57.4% per annum respectively. EPS is expected to grow by 33.5% per annum. Return on equity is forecast to be -46.3% in 3 years.
Key information
47.6%
Earnings growth rate
33.5%
EPS growth rate
Biotechs earnings growth | 32.9% |
Revenue growth rate | 57.4% |
Future return on equity | -46.3% |
Analyst coverage | Low |
Last updated | 06 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 952 | -210 | -877 | -525 | 3 |
12/31/2025 | 341 | -705 | -1,012 | -629 | 4 |
12/31/2024 | 107 | -894 | -1,196 | -776 | 4 |
3/31/2024 | 1 | -764 | -484 | -425 | N/A |
12/31/2023 | 1 | -801 | -469 | -378 | N/A |
9/30/2023 | 0 | -695 | -378 | -289 | N/A |
6/30/2023 | 0 | -707 | -437 | -275 | N/A |
3/31/2023 | 1 | -697 | -368 | -205 | N/A |
12/31/2022 | 0 | -576 | -324 | -178 | N/A |
12/31/2021 | 39 | -322 | -351 | -238 | N/A |
12/31/2020 | 1 | -373 | -197 | -140 | N/A |
12/31/2019 | 0 | -157 | -235 | -131 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688443 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688443 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688443 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688443's revenue (57.4% per year) is forecast to grow faster than the CN market (14.1% per year).
High Growth Revenue: 688443's revenue (57.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688443 is forecast to be unprofitable in 3 years.